Cargando…
BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia
High-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) is an option to consolidate remission in Waldenstrom’s macroglobulinemia (WM), particularly in selected younger patients with chemosensitive disease. BEAM, consisting of BCNU, etoposide, cytarabine, and melphalan, is ofte...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057504/ https://www.ncbi.nlm.nih.gov/pubmed/36983378 http://dx.doi.org/10.3390/jcm12062378 |
_version_ | 1785016383784878080 |
---|---|
author | Heini, Alexander D. Beck, Philipp Bacher, Ulrike Seipel, Katja Zander, Thilo Daskalakis, Michael Pabst, Thomas |
author_facet | Heini, Alexander D. Beck, Philipp Bacher, Ulrike Seipel, Katja Zander, Thilo Daskalakis, Michael Pabst, Thomas |
author_sort | Heini, Alexander D. |
collection | PubMed |
description | High-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) is an option to consolidate remission in Waldenstrom’s macroglobulinemia (WM), particularly in selected younger patients with chemosensitive disease. BEAM, consisting of BCNU, etoposide, cytarabine, and melphalan, is often used as a conditioning regimen. However, problems with BCNU, including pneumotoxicity, tolerance, and availability, necessitate the search for alternatives. In this pilot study, we investigated high-dose chemotherapy with BeEAM, in which BCNU is replaced with high-dose bendamustine as an alternative conditioning regimen in six subsequent patients with WM. Bendamustine treatment was well tolerated without unexpected toxicities. The overall response rate was 6/6 patients (2 very good partial responses (VGPR) and 4 PR). After a median follow-up of 72 months, two (33%) patients relapsed. Median progression-free and overall survivals were not reached, and no severe late-onset toxicities were observed so far. In this pilot study, BeEAM conditioning before ASCT seems feasible, safe, and effective in patients with WM. |
format | Online Article Text |
id | pubmed-10057504 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100575042023-03-30 BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia Heini, Alexander D. Beck, Philipp Bacher, Ulrike Seipel, Katja Zander, Thilo Daskalakis, Michael Pabst, Thomas J Clin Med Article High-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) is an option to consolidate remission in Waldenstrom’s macroglobulinemia (WM), particularly in selected younger patients with chemosensitive disease. BEAM, consisting of BCNU, etoposide, cytarabine, and melphalan, is often used as a conditioning regimen. However, problems with BCNU, including pneumotoxicity, tolerance, and availability, necessitate the search for alternatives. In this pilot study, we investigated high-dose chemotherapy with BeEAM, in which BCNU is replaced with high-dose bendamustine as an alternative conditioning regimen in six subsequent patients with WM. Bendamustine treatment was well tolerated without unexpected toxicities. The overall response rate was 6/6 patients (2 very good partial responses (VGPR) and 4 PR). After a median follow-up of 72 months, two (33%) patients relapsed. Median progression-free and overall survivals were not reached, and no severe late-onset toxicities were observed so far. In this pilot study, BeEAM conditioning before ASCT seems feasible, safe, and effective in patients with WM. MDPI 2023-03-19 /pmc/articles/PMC10057504/ /pubmed/36983378 http://dx.doi.org/10.3390/jcm12062378 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Heini, Alexander D. Beck, Philipp Bacher, Ulrike Seipel, Katja Zander, Thilo Daskalakis, Michael Pabst, Thomas BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia |
title | BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia |
title_full | BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia |
title_fullStr | BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia |
title_full_unstemmed | BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia |
title_short | BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia |
title_sort | beeam conditioning including high-dose bendamustine before autologous stem cell transplantation is safe and effective in patients with waldenstrom’s macroglobulinemia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057504/ https://www.ncbi.nlm.nih.gov/pubmed/36983378 http://dx.doi.org/10.3390/jcm12062378 |
work_keys_str_mv | AT heinialexanderd beeamconditioningincludinghighdosebendamustinebeforeautologousstemcelltransplantationissafeandeffectiveinpatientswithwaldenstromsmacroglobulinemia AT beckphilipp beeamconditioningincludinghighdosebendamustinebeforeautologousstemcelltransplantationissafeandeffectiveinpatientswithwaldenstromsmacroglobulinemia AT bacherulrike beeamconditioningincludinghighdosebendamustinebeforeautologousstemcelltransplantationissafeandeffectiveinpatientswithwaldenstromsmacroglobulinemia AT seipelkatja beeamconditioningincludinghighdosebendamustinebeforeautologousstemcelltransplantationissafeandeffectiveinpatientswithwaldenstromsmacroglobulinemia AT zanderthilo beeamconditioningincludinghighdosebendamustinebeforeautologousstemcelltransplantationissafeandeffectiveinpatientswithwaldenstromsmacroglobulinemia AT daskalakismichael beeamconditioningincludinghighdosebendamustinebeforeautologousstemcelltransplantationissafeandeffectiveinpatientswithwaldenstromsmacroglobulinemia AT pabstthomas beeamconditioningincludinghighdosebendamustinebeforeautologousstemcelltransplantationissafeandeffectiveinpatientswithwaldenstromsmacroglobulinemia |